#	Pagina
attuale pagina	/open-h2020/projects/212673/index.html

Opendata, web and dolomites

CONVINCE SIGNED

The Comparison of High-Dose Heamodiafiltration (HDF) versus Haemodialyse

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CONVINCE project word cloud

Explore the words cloud of the CONVINCE project. It provides you a very rough idea of what is the project "CONVINCE" about.

regenerative ranks diseases medicine paper decade publish substantial function endpoints definite gives idea replacement stage hemodialysis question cardiovascular infections consequence effecticvely patients normal dialysis dose end became accepted fatal clinical unmet effort superiority versus hospitalisation annual patient quality treatment put land chronic rates medical prospective care kidney stable answer mortality randomized society everyday money lacking strategies 10 utility prevent standard improvement therapy removes guideline 15 haemodialysis alternative transplantation urgently severe trial majority disease below proof vast burden haemodialfiltration conventional progression experimental risks mark regulatory intervention small haemodiafiltration supports life waste communicable accumulated

Project "CONVINCE" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITAIR MEDISCH CENTRUM UTRECHT Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX website: www.umcutrecht.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.convincetrial.eu
Total cost	6˙865˙425 €
EC max contribution	6˙440˙488 € (94%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2017-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2018
Duration (year-month-day)	from 2018-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITAIR MEDISCH CENTRUM UTRECHT UNIVERSITAIR MEDISCH CENTRUM UTRECHT Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX website: www.umcutrecht.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	coordinator	573˙062.00
2	JULIUS CLINICAL RESEARCH BV JULIUS CLINICAL RESEARCH BV Organization address address: BROEDERPLEIN 41-43 city: ZEIST postcode: 3703 CD website: www.juliusclinical.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ZEIST)	participant	2˙256˙001.00
3	FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH Organization address address: ELSE KROENER STRASSE 1 city: BAD HOMBURG postcode: 61352 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BAD HOMBURG)	participant	850˙675.00
4	DIAVERUM SWEDEN AB DIAVERUM SWEDEN AB Organization address address: TROLLEBERGSVAGEN 5 city: LUND postcode: 227 22 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (LUND)	participant	701˙550.00
5	CHARITE - UNIVERSITAETSMEDIZIN BERLIN CHARITE - UNIVERSITAETSMEDIZIN BERLIN Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 website: www.charite.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	555˙127.00
6	B.Braun Avitum AG B.Braun Avitum AG Organization address address: SCHWARZENBERGER WEG 73-79 city: MELSUNGEN postcode: 34212 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MELSUNGEN)	participant	510˙537.00
7	ROYAL FREE LONDON NHS FOUNDATION TRUST ROYAL FREE LONDON NHS FOUNDATION TRUST Organization address address: POND STREET HAMPSTEAD city: LONDON postcode: NW3 2QG website: http://www.royalfree.nhs.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	413˙593.00
8	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	361˙190.00
9	UNIVERSITY COLLEGE LONDON UNIVERSITY COLLEGE LONDON Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	209˙063.00
10	UNIVERSITA DEGLI STUDI DI BARI ALDO MORO UNIVERSITA DEGLI STUDI DI BARI ALDO MORO Organization address address: PIAZZA UMBERTO I 1 city: BARI postcode: 70121 website: www.uniba.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (BARI)	participant	9˙687.00

Map

Project objective

End stage kidney disease ranks among the most severe chronic non-communicable diseases with an unmet medical need, given the high (between 10 and 15%) and stable annual mortality rates. Kidney replacement therapy is necessary when kidney function is below 10% of the normal value. Much effort is put into developing strategies to prevent chronic kidney disease progression. Regenerative medicine still is in the experimental phase and kidney transplantation is only available for a small number of patients. Indeed, the everyday reality is the growing number of dialysis patients. Haemodialysis treatment is the current standard of care for the vast majority of patients with end stage kidney disease. It is a substantial burden to the patient and for society. Haemodialysis treatment is associated with high risks for fatal and non-fatal cardiovascular disease, for infections, hospitalisation and low quality of life. Improvement in the currently available standard is urgently needed.

Over the past decade an alternative for haemodialysis became available, i.e. haemodiafiltration. Both are accepted by regulatory authorities. Haemodiafiltration removes waste products that are accumulated due to kidney failure, more effecticvely than standard hemodialysis. Present evidence supports the idea of superiority of haemodialfiltration compared to standard haemodialysis. However, definite proof is lacking and as a consequence haemodiafiltration is not yet widely applied.

This consortium aims to determine the best possible dialysis treatment by comparing the conventional guideline based haemodialysis treatment versus high-dose haemodiafiltration by carrying out a prospective randomized controlled clinical trial addressing clinical endpoints, quality of life and a cost-utility analysis. The study will deliver an answer on the question which intervention gives the best value for money. Therefore, it will be considered a “land mark” study, allowing to publish an “end of discussion” paper

Deliverables

List of deliverables.
Project plan with general description of RCT, also including inclusion and exclusion criteria	Documents, reports	2020-04-17 18:13:36
Project logo and website	Websites, patent fillings, videos etc.	2020-04-07 22:44:45
Rationale and study paper	Documents, reports	2020-04-07 22:44:45

Take a look to the deliverables list in detail: detailed list of CONVINCE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONVINCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONVINCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination